Progeneer
Pioneering Breakthroughs in Biotechnology for Advanced Adjuvant Platforms

Progeneer, a prominent Korean start-up, is creating a wave in the biotechnology sector with its revolutionary vaccine adjuvants and cell-free protein synthesis technologies. Their vaccine adjuvants play a crucial role in enhancing the effectiveness of vaccines by stimulating the immune response.

“Our revolutionary technologies in vaccine adjuvants and cell-free protein synthesis are driving innovation in the biotechnology industry. With a focus on personalized cancer vaccines and advanced adjuvant platforms, we are filling crucial gaps and revolutionizing the fight against diseases,” says Chul Kim, CEO.

Progeneer offers two core platforms—cell-free protein synthesis (CFPs) and lipid nano platform. CFPs, also known as in vitro translation, have been utilized for some time but faced limitations in terms of efficiency. Progeneer aims to overcome these limitations by applying hydrogel techniques, enabling the continuous expression of proteins and removal of waste. This approach opens doors for rapidly developing personalized treatment options, such as individualized cancer vaccines, significantly reducing the turnaround time from months to weeks.

ProLNG, the lipid nano platform developed by Progeneer, is a proprietary technology that shows great promise in the vaccine domain. It involves capping the active site of TLR7/8 agonists with cholesterol through a cleavable link. This innovation overcomes the distribution, toxicity, and formulation challenges associated with TLR7/8 agonists. By selectively releasing the active site, ProLNG ensures controlled activation of the TLR pathway, enhancing immune responses.

It can be easily incorporated into liposomes or lipid nanoparticles, making it compatible with treatments like mRNA vaccines.

The complexity of the vaccine value chain involves optimizing the antigen and delivery process and immune potentiation. To address this, Progeneer collaborates with various partners to develop diverse platforms of action, including peptides, proteins, mRNA, and different delivery methods such as lipid nanoparticles.

Progeneer has drastically reduced the turnaround time for producing individualized protein antigens. It can deliver target protein antigens in 4 to 5 weeks, enabling timely and personalized treatments for cancer patients. This remarkable achievement marks a significant advancement in the field and provides hope for improved patient outcomes.

These ground-breaking technologies have already demonstrated their potential benefits in practical applications. For instance, the company has collaborated with traditional vaccine developers and companies focused on mRNA vaccines for cancer. By combining ProLNG with mRNA vaccine platforms, Progeneer achieves strong immune stimulation along with effective antigen presentation. This approach offers an alternative that complements existing strategies and meets the specific requirements of personalized cancer vaccines.

The driving force behind Progeneer’s innovation lies in its determination to fill the gaps in the biotechnology landscape. The company recognizes the importance of addressing essential components, such as antigen development, appropriate delivery platforms, and immune stimulation. While many focus on well-known areas, Progeneer believes in the power of concentrating on relatively neglected aspects to hit the target and achieve common objectives. Its team culture revolves around a focused and integrated approach, driving Progeneer’s commitment to bridging critical gaps in antigen development.

Progeneer’s advancements in personalized cancer vaccines and innovative adjuvant platform, ProLNG, demonstrate its dedication to pushing the boundaries of biotechnology. Its rapid protein synthesis system and controlled release technology hold great promise for improving patient outcomes and revolutionizing the field of vaccine development. Progeneer’s contributions have the potential to reshape the landscape of cancer treatment and advance global health initiatives.